Clearside Biomedical licenses SCS Microinjector to BioCryst for avoralstat in DME

Clearside Biomedical, Inc.

Clearside granted BioCryst exclusive worldwide license to use SCS Microinjector for avoralstat in diabetic macular edema.
Upfront fee of $5.0 million; eligible for up to $30.0 million in clinical/regulatory milestones and $47.5 million in sales-based milestones.
Tiered mid-single digit royalties on annual global net sales, highest rate on sales over $1.5 billion.
BioCryst responsible for all development, regulatory, and commercialization; Clearside to supply SCS Microinjectors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Clearside Biomedical, Inc. entered into License Agreement with BioCryst Pharmaceuticals, Inc. valued at Upfront license fee of $5.0 million, clinical and regulatory milestones up to $30.0 million, sales-b (effective 2023-11-01).

Action: entry
Agreement: license
Counterparty: BioCryst Pharmaceuticals, Inc.
Value: Upfront license fee of $5.0 million, clinical and regulatory milestones up to $30.0 million, sales-b
Effective: 2023-11-01

Exact text from the filing

On November 1, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a license agreement (the “ License Agreement ”) with BioCryst Pharmaceuticals, Inc. (“ BioCryst ”) pursuant to which the Company granted BioCryst an exclusive, worldwide and sublicensable license to the Company’s SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and prevention of diabetic macular edema (“ DME ”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-058627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.